AstraZeneca and Daiichi Sankyo Initiate DESTINY-Gastric05 Study for Enhertu in Metastatic Gastric Cancer
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the first patient dosing in...
AstraZeneca
AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi...
AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment
UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National...
AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China
UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its...
Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with...
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a...
AstraZeneca Unveils USD2.5 Billion Beijing R&D Center Plan Amid Strategic China Partnerships
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has announced a five-year plan to invest USD 2.5...
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca...
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan....
AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for...
AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....
AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...
AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...
Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline
Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...
Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines
China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...
FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...
AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...